Search CORE

4 research outputs found

Factor VIII inhibitor bypassing activity (FEIBA) – addressing safety issues

Author: Aledort L
Brackmann HH
Dargaud Y
Dorner F
Ewing N
Goudemand J
Hilgartner MW
Negrier C
Sjamsoedin LJM
Varadi K
Publication venue: 'Wiley'
Publication date
Field of study

Activated prothrombin complex concentrate (FEIBAR) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience

Author: Bech RBM
Blatt PM
Blatt PM
Hanna WT
Heisel MA
Hutchinson RJ
Lusher JM
Negrier C
Penner JA
Schwartz RS
Sjamsoedin LJM
Yolken RH
Publication venue: 'Wiley'
Publication date
Field of study

FEIBAR safety profile in multiple modes of clinical and home-therapy application

Author: Aledort LM.
Baxter Healthcare Corporation.
Dorner F
Escuriola-Ettingshausen C
Hemker HC
Hilgartner MW
Junonen E
Key NS
Kreuz W
Kreuz W
Negrier C
Negrier C
Nilsson IM
Rosenfeld SB
Schneiderman J
Sjamsoedin LJM
Waytes AT
Publication venue: 'Wiley'
Publication date
Field of study

Immune tolerance therapy in paediatric haemophiliacs with factor VIII inhibitors: 14 years follow-up

Author: Brackman HH.
Brackmann HH.
Ewing NP.
Hedner U.
Kasper CK.
Kasper CK.
Langdell RD.
Leeuwen EF.
Lusher JM.
Mariani G.
Mauser-Bunschoten EP.
Rasi V.
Rizza CR.
Scheibel E.
Schwartz RS.
Sjamsoedin LJM.
Sultan Y.
Wensley RT.
Publication venue: 'Wiley'
Publication date
Field of study

core

core